3930-19-6
Chemical Structure
Streptonigrin
Synonym(s): Bruneomycin
- CAS No.: 3930-19-6
- Formula:C25H22N4O8
- Molecular Weight:506.46
IUPAC Name: 5-amino-6-(7-amino-6-methoxy-5,8-dioxo-5,8-dihydroquinolin-2-yl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpicolinic acid
InChIKey: PVYJZLYGTZKPJE-UHFFFAOYSA-N
SMILES: O=C(C1=NC(C2=NC3=C(C(C(OC)=C(N)C3=O)=O)C=C2)=C(N)C(C4=CC=C(OC)C(OC)=C4O)=C1C)O
Biological Activity: Streptonigrin (Bruneomycin) is an orally active antibiotic and pan-PAD inhibitor, inhibiting PAD1, PAD2, PAD3 and PAD4 with IC50 of 48.3 μM, 26.1 μM, 0.43 μM and 2.5 μM, respectively. Streptonigrin inhibits SENP1 (IC50 of 0.518 μM) and reduces HIF1α. Streptonigrin increases p53 and Apoptosis. Streptonigrin shows antiviral activity against Rauscher murine leukemia virus. Streptonigrin has immunosuppressive effects. Streptonigrin has antitumor activity against osteosarcoma[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Streptonigrin | 99.9% | Streptonigrin (Bruneomycin) is an orally active antibiotic and pan-PAD inhibitor, inhibiting PAD1, PAD2, PAD3 and PAD4 with IC50 of 48.3 μM, 26.1 μM, 0.43 μM and 2.5 μM, respectively. Streptonigrin inhibits SENP1 (IC50 of 0.518 μM) and reduces HIF1α. Streptonigrin increases p53 and Apoptosis. Streptonigrin shows antiviral activity against Rauscher murine leukemia virus. Streptonigrin has immunosuppressive effects. Streptonigrin has antitumor activity against osteosarcoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Dreyton CJ, et al. Insights into the mechanism of Streptonigrin-induced protein arginine deiminase inactivation. Bioorg Med Chem. 2014 Feb 15;22(4):1362-9. [Content Brief]
- [2]. Park S, et al. Streptonigrin inhibits β-Catenin/Tcf signaling and shows cytotoxicity in β-catenin-activated cells. Biochim Biophys Acta. 2011 Dec;1810(12):1340-5. [Content Brief]
- [3]. Piatakova NV, et al. Soluble guanylate cyclase in the molecular mechanism underlying the therapeutic action of drugs]. Biomed Khim. 2012 Jan-Feb;58(1):32-42. Russian. [Content Brief]
- [4]. Ambaye N, et al. Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1α (HIF1α) in Cells. Biochemistry. 2018 Mar 20;57(11):1807-1813. [Content Brief]
- [5]. Loyola AC, et al. Streptonigrin at low concentration promotes heterochromatin formation. Sci Rep. 2020 Feb 26;10(1):3478. [Content Brief]
- [6]. Yamashita Y, et al. Induction of mammalian DNA topoisomerase II dependent DNA cleavage by antitumor antibiotic streptonigrin. Cancer Res. 1990 Sep 15;50(18):5841-4. [Content Brief]
- [7]. McBride TJ, et al. The activity of streptonigrin against the Rauscher murine leukemia virus in vivo. Cancer Res. 1966 Apr;26(4):727-32. [Content Brief]
- [8]. Suzuki H, et al. Immunosuppressive activity of streptonigrin in vitro and in vivo. Biosci Biotechnol Biochem. 1996 May;60(5):789-93. [Content Brief]
- [9]. Kang JH, et al. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma. Cells. 2020 Jun 16;9(6):1475. [Content Brief]
- [10]. Long GV, et al. Interaction of the antitumour antibiotic streptonigrin with DNA and oligonucleotides. Anticancer Drug Des. 1997 Sep;12(6):453-72. [Content Brief]
Keywords
